Navigation Links
Rigel to Webcast Investor Update on October 27, 2008
Date:10/21/2008

SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will webcast its investor update, in conjunction with the American College of Rheumatology Meeting (ACR), on October 27, 2008 from 2:00-3:00pm Pacific Time. Members of Rigel's senior management team will provide an update on the company's lead product candidate, R788, a novel, oral Syk kinase inhibitor. R788 is currently being evaluated in two Phase 2b clinical trials in patients with rheumatoid arthritis, as well as Phase 2 clinical trials in immune thrombocytopenic purpura and B-cell lymphomas.

The event will be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary. The webcast will be archived and available for replay on the Company's website.

In addition, Rigel will be participating in both a plenary session and a poster session during ACR in San Francisco, California from October 24-29, 2008.

ACR Presentation Details

Plenary session: Monday, Oct 27, 12:15-12:30 PM

Session: Discovery 2008: Pathogenesis and Treatment of Inflammatory

Arthritis

Title: 1189 - Treatment of Rheumatoid Arthritis (RA) with a Syk Kinase

Inhibitor: A 12-week randomized placebo controlled study

Location: Hall C

Poster session: Tuesday, Oct 28, 9:00-11:00 AM

Session: Biology and Pathology of Bone and Cartilage

Title: 1293 - R406, a Small Molecule Syk inhibitor, Suppresses Osteoclast

Differentiation of Murine Bone Mar
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Rigel Announces Third Quarter 2007 Financial Results
2. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
3. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
4. Rigel Announces Offering of 4,000,000 Shares of Common Stock
5. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
6. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
7. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
8. Rigel Announces First Quarter 2008 Financial Results
9. Rigel to Present at Collins Stewart Growth Conference
10. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
11. Webcast Alert: Kaiser Permanente Residency Program Open House
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... proportion of patients with advanced cancer and a life ... common cancer screening tests that are unlikely to provide ... 13 issue of JAMA . Cancer ... (PSA) and colonoscopy, evaluate asymptomatic patients for the detection ...
... Goodwin HealthDay Reporter , TUESDAY, Oct. 12 (HealthDay ... transfusions do just as well as those who receive more, ... varies widely among U.S. hospitals. The studies are published ... the American Medical Association . In the first study, ...
... GABLES, FL (October 12, 2010)--Still hampered by workforce shortages ... care to the full extent of their education and ... the arm they need to transform their profession with ... recommending sweeping changes for improving their profession. The report, ...
... By Kathleen Doheny HealthDay Reporter , TUESDAY, Oct. ... cancer care has long been known by researchers, with ... cancer treatments than white patients. "Less well known is ... something else contributing?" said Dr. Rachel Freedman, a medical ...
... of a large Phase-III clinical trial have shown that ... a hard-to-treat group of rare cancers that affect particular ... European Society for Medical Oncology (ESMO), Dr Marianne Pavel ... improved progression-free survival by 5.1 months in patients with ...
... population ages, health care epidemiologist Padma Kaul and cardiologist Paul ... the University of Alberta, want health-care professionals to talk to ... it be at home, in hospital or a palliative care ... recent study, that the majority of heart failure patients pass ...
Cached Medicine News:Health News:Considerable proportion of patients with advanced cancer continue to undergo common cancer screening 2Health News:Considerable proportion of patients with advanced cancer continue to undergo common cancer screening 3Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:National committee releases findings on transforming and improving the nursing profession 2Health News:Insurance, Income Don't Explain 'Race Gap' in Breast Cancer Care 2Health News:Insurance, Income Don't Explain 'Race Gap' in Breast Cancer Care 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2Health News:Medical researchers break down costs to care for heart failure patients at the end of life 2
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
The CE marked HF coagulator which meets the highest ISO safety features....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Medicine Products: